HILDEN, Germany and GERMANTOWN, Maryland, June 2, 2016
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the formation of a global consortium of international lung cancer experts who will advise the company on the design of new next-generation sequencing (NGS) gene panels and associated workflows that target lung cancer-specific mutations.
The members of the consortium will work with a QIAGEN team to guide selection of the genes and variants for the panels, development of the NGS workflows, and the verification of both the panels and workflows. The results of these validation studies will be published by the Expert Alliance. From the work of the consortium, QIAGEN will deliver a series of Sample to Insight lung cancer NGS panel workflows for use with both tissue and liquid biopsy samples on QIAGEN's GeneReader NGS System, the world's first truly complete NGS workflow - from Sample to Insight.
Click here for full press release
Public Relations: Dr. Thomas Theuringer Senior Director Public Relations +49-2103-29-11826 Email: [email protected] http://www.twitter.com/qiagen https://www.facebook.com/QIAGEN pr.qiagen.com
Investor Relations: John Gilardi Vice President Corporate Communications and Investor Relations +49-2103-29-11711 Email: [email protected] ir.qiagen.com
SOURCE QIAGEN N.V.
Subscribe to our Free Newsletters!
Strokes occur when blood flow to an area of the brain is cut off. It is imperitive to detect the ...
Bile duct cancer occurs either within the liver or the point where the bile ducts emerge from the ...
Xeroderma pigmentosum is a rare inherited condition marked by extreme sensitivity to sunlight and ...View All